In many parts of the world, incidence of papillary thyroid cancer is increasing faster than any
other malignancy. Most papillary thyroid cancers that are diagnosed are small and are …

Background Central lymph node metastasis (CLNM) is common in papillary thyroid
carcinoma (PTC). Prophylactic central lymph node dissection (PCLND) for patients with …

Background Lymph node metastasis (LNM) is frequent in papillary thyroid carcinoma (PTC)
and is associated with a poor prognosis. Unlike central LNM (CLNM), there are few studies …

Thyroid cancers have long been considered to arise in middle age and, after their repeated
proliferation, resulting in further damage to the genome, they progress to more aggressive …

Purpose: A multicenter, open-label, phase II trial was conducted to evaluate the efficacy,
safety, and tolerability of selumetinib in iodine-refractory papillary thyroid cancer (IRPTC) …

Lenvatinib significantly prolonged progression‐free survival (PFS) versus placebo in
patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC) in the phase 3 …

Background Although papillary thyroid carcinoma (PTC) often presents as multifocal or
bilateral tumors, but whether multifocality or bilaterality is associated with disease …

Follicular thyroid carcinoma (FTC) has different clinicopathological characteristics than
papillary thyroid carcinoma. However, there are no independent systems to predict cancer …

Until recently, no truly effective treatment options have existed for patients with radioactive
iodine (RAI)-refractory differentiated thyroid cancer (DTC), a serious disease with poor …

The study aimed to identify the clinical characteristics of coexisting chronic lymphocytic
thyroiditis (CLT) in papillary thyroid carcinoma (PTC) and to evaluate the influence on …